Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

BACKGROUND: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been implicated in resistance to BEV. This phase II study...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Hao, Lafky, Jacqueline M., Morlan, Bruce W., Stella, Philip J., Dakhil, Shaker R., Gross, Gerald G., Loui, William S., Hubbard, Joleen M., Alberts, Steven R., Grothey, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066587/
https://www.ncbi.nlm.nih.gov/pubmed/32201506
http://dx.doi.org/10.1177/1758835920910913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066587/
https://www.ncbi.nlm.nih.gov/pubmed/32201506
http://dx.doi.org/10.1177/1758835920910913

Ejemplares similares